Evidence map›Paper›PMID 32983259›Full record

ArticleBioData mining2020

Therapeutic mechanism of Toujie Quwen granules in COVID-19 based on network pharmacology.

Ying Huang, Wen-Jiang Zheng, Yong-Shi Ni, Mian-Sha Li, Jian-Kun Chen, Xiao-Hong Liu, Xing-Hua Tan, Ji-Qiang Li

Open access · goldAbstract read
In one paragraph

Article in BioData mining, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Article
  7. Review
  8. Article
  9. Flavonoids against the SARS-CoV-2 induced inflammatory storm.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ying Huang *First College of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Wen-Jiang Zheng *First College of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Yong-Shi NiThe Second College of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Mian-Sha LiTianhe Shadong Street Community Healthcare Service Center, Guangzhou, China.ORCID 0000-0003-3726-3720
Jian-Kun ChenIntegrative Dept.3 (Geriatrics Dept), Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Xiao-Hong LiuFirst College of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
Xing-Hua TanDepartment of Traditional Chinese Medicine, Guangzhou Eighth People's Hospital, Guangzhou, China.
Ji-Qiang LiIntegrative Dept.3 (Geriatrics Dept), Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Guangzhou University of Chinese Medicine · CNGuangdong Provincial Hospital of Traditional Chinese Medicine · CNGuangzhou Eighth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChinese medicine Toujie Quwen granule (TJQW) has proven to be effective in the treatment of mild coronavirus disease 2019 (COVID-19) cases by relieving symptoms, slowing the progression of the disease, and boosting the recovery of patients. But the bioactive compounds and potential mechanisms of TJQW for COVID-19 prevention and treatment are unclear. This study aimed to explore the potential therapeutic mechanism of TJQW in coronavirus disease 2019 (COVID-19) based on an integrated network pharmacology approach.

methodsTCMSP were used to search and screen the active ingredients in TJQW. The Swiss TargetPrediction was used to predict the potential targets of active ingredients. Genes co-expressed with ACE2 were considered potential therapeutic targets on COVID-19. Venn diagram was created to show correlative targets of TJQW against COVID-19. Cytoscape was used to construct a "drug-active ingredient-potential target" network, STRING were used to construct protein-protein interaction network, and cytoHubba performed network topology analysis. Enrichment of biological functions and signaling pathways of core targets was performed by using the clusterProfiler package in R software and ClueGO with CluePedia plugins in Cytoscape.

resultsA total of 156 active ingredients were obtained through oral bioavailability and drug-likeness screenings. Two hundred twenty-seven potential targets of TJQW were related to COVID-19. The top ten core targets are EGFR, CASP3, STAT3, ESR1, FPR2, F2, BCL2L1, BDKRB2, MPO, and ACE. Based on that, we obtained 19 key active ingredients: umbelliprenin, quercetin, kaempferol, luteolin, praeruptorin E, stigmasterol, and oroxylin A. And the enrichment analysis obtained multiple related gene ontology functions and signaling pathways. Lastly, we constructed a key network of "drug-component-target-biological process-signaling pathway". Our findings suggested that TJQW treatment for COVID-19 was associated with elevation of immunity and suppression of inflammatory stress, including regulation of inflammatory response, viral process, neutrophil mediated immunity, PI3K-Akt signaling pathway, MAPK signaling pathway, Jak-STAT signaling pathway, Complement and coagulation cascades, and HIF-1 signaling pathway.

conclusionsOur study uncovered the pharmacological mechanism underlying TJQW treatment for COVID-19. These results should benefit efforts for people around the world to gain more knowledge about Chinese medicine TJQW in the treatment of this vicious epidemic COVID-19, and help to address this pressing problem currently facing the world.

Indexed as

COVID-19Network pharmacologyPotential therapeutic targetsSignaling pathwaysToujie Quwen granule

Identifiers

PMID32983259
PMCPMC7512049
OpenAlexW3088083424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.